Pharma BD Deal Intelligence
Kalexo Bio, Inc. / Mabwell (Shanghai) Bioscience Co., Ltd.
2025 · Licensing/Option · $1.0B · Complete
Mabwell Bioscience and Aditum Bio announced the formation of Kalexo Bio, a NewCo launched around an exclusive global license to 2MW7141, a dual-target siRNA candidate for lipid management in patients with dyslipidemia. Trade press reported total deal value of up to approximately USD 1 billion; the upfront component was not disclosed.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Sep 17, 2025
- Deal value $1.0B
- Deal type Licensing/Option
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals